The United States Centers for Disease Control and Prevention issued a statement regarding the Johnson & Johnson/Janssen Covid-19 vaccine, sharing that approximately 100 individuals suffered from a rare neurologic disorder called Guillain-Barre syndrome after receiving this vaccine.
The United States Centers for Disease Control and Prevention issued a statement regarding the Johnson & Johnson/Janssen Covid-19 vaccine, sharing that approximately 100 individuals suffered from a rare neurologic disorder called Guillain-Barre Syndrome (GBS) after receiving this vaccine. Close to 13 million Johnson & Johnson vaccines have been administered to date in the U.S. The CDC’s statement sent to Insider was as follows: « Reports of GBS after receipt of the J&J/Janssen COVID-19 Vaccine in the Vaccine Adverse Event Reporting System (VAERS) are rare, but do likely indicate a small possible risk of this side effect following this vaccine. These cases have largely been reported about two weeks after vaccination and mostly in males, many aged 50 years and older. » This is the second major blow to this single-dose vaccine. On April 12, 2021, the CDC and Food and Drug Administration (FDA) issued a joint statement to pause the use of this vaccine after several cases of a rare form of life-threatening blood clot, known as CVST, or cerebral venous sinus thrombosis, afflicted several individuals, primarily women between the ages and 18 and 48. Three of these women died.
